Objectives: To evaluate the results of antiandrogen and bisphosphonate therapy in treatment of bone metastatic prostate cancer. Subjects and methods: A prospective clinical interventive study on 44 newly diagnosed bone metastatic prostate cancer patients at the 108 Military Central Hospital from July 2010 to July 2018. | Journal of military pharmaco-medicine no1-2019 RESULTS OF ANTIANDROGEN AND BIPHOSPHONATE THERAPY IN TREATMENT OF BONE METASTATIC PROSTATE CANCER IN 108 MILITARY CENTRAL HOSPITAL La Van Truong1; Tran Van Ton2 SUMMARY Objectives: To evaluate the results of antiandrogen and bisphosphonate therapy in treatment of bone metastatic prostate cancer. Subjects and methods: A prospective clinical interventive study on 44 newly diagnosed bone metastatic prostate cancer patients at the 108 Military Central Hospital from July 2010 to July 2018. Results: of the study patients was 65 years old, had combined disease, had severe urinary disorders, 50% had bone pain and had systemic condition at 1 - 2 points. At the time of diagnosis: had PSA ≥ 20 ng/mL, had Gleason ≥ 8 points, cT4, had only bone metastases, had bone metastases and nodal metastases or organ metastases. Spinal and pelvic bones were the two most frequent metastases ( and ); of patients had testicular cut, had PSA response, had PSA nadir ≤ 4 ng/mL; median non-progressive survival and median overall survival were months and months. Conclusions: Most patients with bone metastatic prostate cancer had testicular cut and PSA response in antiandrogen and pamisol therapy, however, the median non-progressive survival was short. * Keywords: Prostate cancer; Bone metastases; Antiandrogen; Bisphosphonate. INTRODUCTION Prostate cancer is one of the common cancers. According to Globocan 2012, the rate of prostate cancer is the second highest in the world and the 10th in Vietnam. As with most cancers, the treatment strategy for prostate cancer is multidisciplinary treatment, combining several therapies: surgery, radiation, antiandrogen, chemotherapy, and treatment. The specific treatment options are based on the stage of the disease, the risk level, the prognostic factors, the expectation of survival, the condition of the patient. .
